INSIGHTS

After coronavirus, AI could be central to our new normal

Issue 14 - Special Report Series - Part Three

The content and distribution of Azafran’s INSIGHTS newsletter is focused to our LP, incubator, research, investment and partner ecosystem. As we look to build a two-way dialogue benefitting our collective efforts, each month we highlight important news and our approach to the emerging intersection of deep technology, end to end solutions and platforms driven by voice, acoustics and imagery.

This article is one section of an entire issue of INSIGHTS. Please sign up to receive access to past and new issues as they are published.

Subscribe to our newsletter

(VentureBeat) When we came out of the financial crisis of 2008, cloud computing kicked into high gear and started to become a pervasive, transformational technology. The current COVID-19 crisis could provide a similar inflection point for AI applications. While the implications of AI continue to be debated on the world stage, the rapid onset of a global health crisis and concomitant recession will accelerate its impact.

Times of crisis bring rapid change. Efforts to harness AI technologies to discover new drugs – either vaccine or treatment – have kicked into hyperdrive. Startups are racing to find solutions and established companies are forming partnerships with academia to find a cure. Other companies are researching existing drugs for their potential applicability.

AI is proving a useful tool for dramatically reducing the time needed to identify potential drug candidates, possibly saving years of research. AI uses already put into action are screening for COVID-19 symptoms, decision support for CT scans, and automating hospital operations. A variety of healthcare functions have started to be performed by robots, from diagnosis to temperature monitoring.


© Copyright 2017 - 2020, Azafran Capital Partners, Inc.